Idiopathic Pulmonary Fibrosis Market, By Drug (Pirfenidone, Nintedanib, Others (Interferon gamma-1b and Others)), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Phamacies), and By Geo
Description
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.
Market Dynamics
Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2021, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2020. About 100,000 people were affected in the U.S., in 2020, whereas 30,000 to 40,000 new cases are diagnosed every year.
According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2021.
Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech’s, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies
Key features of the study:
Market Dynamics
Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2021, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2020. About 100,000 people were affected in the U.S., in 2020, whereas 30,000 to 40,000 new cases are diagnosed every year.
According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2021.
Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech’s, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies
Key features of the study:
- This report provides in-depth analysis of the global Idiopathic pulmonary fibrosis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market
- Global Idiopathic pulmonary fibrosis market, By Drug:
- Pirfenidone
- Nintedanib
- Others (Interferon gamma-1b and Others)
- Global Idiopathic pulmonary fibrosis market, By Route of Administration:
- Oral
- Parenteral
- Global Idiopathic pulmonary fibrosis market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Idiopathic pulmonary fibrosis market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Genentech, Inc.
- Boehringer Ingelheim International GmbH
- Avalyn Pharma, Inc.
- AstraZeneca
- Blade Therapeutics
- Bristol-Myers Squibb Company
- Cipla Inc.
- Hoffmann-La Roche
- FibroGen, Inc.
- Galapagos NV
- MediciNova, Inc.
- Merck & Co., Inc.
- Promedior, Inc.
- Prometic Life Sciences Inc.
- Daewoong Pharmaceutical (India) Pvt Ltd
- Sandoz International GmbH (Novartis)
- Algernon Pharmaceuticals Inc.
Table of Contents
339 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Product Launches
- Merger, Acquisition, Collaboration
- Regulatory Guideline and Compliances
- Key Developments
- Market Trends
- PEST Analysis
- Epidemiology
- PORTER’s Analysis
- Regulatory Scenario
- Brand Analysis
- Pricing Analysis
- Pipeline Analysis
- 4. Global Idiopathic Pulmonary Fibrosis Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
- 5. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2020 – 2032, (US$ Million)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 – 2032
- Segment Trends
- Pirfenidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
- Nintedanib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
- Others (Interferon gamma-1b and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
- 6. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2020 – 2032, (US$ Million)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 – 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
- 7. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2020 – 2032, (US$ Million)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 – 2032
- Segments Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
- 8. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2020 – 2032, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021–2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2020 – 2032, (US$ Million)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim International GmbH.
- Avalyn Pharma, Inc.
- AstraZeneca
- Blade Therapeutics
- Bristol-Myers Squibb Company
- Cipla Inc.
- F. Hoffmann-La Roche
- FibroGen, Inc.
- Galapagos NV
- MediciNova, Inc.
- Merck & Co., Inc.
- Promedior, Inc.
- Prometic Life Sciences Inc.
- Daewoong Pharmaceutical (India) Pvt Ltd
- Sandoz International GmbH (Novartis)
- Algernon Pharmaceuticals Inc.
- 10. Section
- Research Methodology
- About Us
- *Browse 58 market data tables and 53 figures on “Global Idiopathic Pulmonary Fibrosis Market”- Global forecast to 2032
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
